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ABSTRACT
Introduction: Irritable bowel syndrome (IBS) is
a functional bowel disorder characterized by
chronic or recurrent abdominal pain in
association with defecation or a change in
bowel habits. A predominant disorder of bowel
habits, IBS is classified into three main subtypes:
constipation-predominant IBS (IBS-C),
diarrhea-predominant IBS (IBS-D) and IBS
alternating between constipation and diarrhea
(IBS-M). Linaclotide is a first-in-class, oral,
once-daily guanylate cyclase-C receptor
agonist (GC-CA) that is licensed for the
symptomatic treatment of moderate-to-severe
IBS-C in adults. This review aims to facilitate
and optimize clinical practices, establishing
common guidelines to monitor patients with
IBS-C that are treated with linaclotide.
Methods: A group of experts in functional
digestive disorders was convened to review the
efficacy and safety of linaclotide and to develop
an updated consensus report for the treatment
of patients with IBS-C. A search was performed
for English, French and Spanish language
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articles in PubMed. On the basis of the articles
identified, an initial document was drafted
addressing different issues frequently raised by
general practitioners and GI specialists that are
related to the prescription, efficacy and safety of
linaclotide. This document was then reviewed
and modified by the expert panel until a final
text was agreed upon and validated.
Results: Based on the evidence, the panel
addressed the following recommendations: (1)
Linaclotide is indicated for the treatment of
moderate to severe IBS-C in adults; (2) it is
recommended that patients take linaclotide
continuously and not sporadically; (3) patients
should be warned about the risk of diarrhea and
given choices concerning how to deal with this
possible side effect; (4) the absence of
tachyphylaxis or potential risks implies that
linaclotide treatment can be maintained for
long periods of time.
Conclusions: This document seeks to lay down
a set of recommendations and to identify key
issues that may be useful for the clinical
management of IBS-C patients treated with
linaclotide.
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Constipation; Constipation-predominant
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INTRODUCTION
Irritable bowel syndrome (IBS) is a chronic
functional disorder characterized by chronic or
recurrent abdominal pain due to bloating/
distention and associated with defecation or a
change in bowel habits (i.e., constipation,
diarrhea, or a mix of constipation and
diarrhea) [1]. This is a relatively common
gastrointestinal disorder detected worldwide,
and its prevalence in the general population
ranges from 3% to 21% depending on the
criteria used to define IBS. Accordingly, the
prevalence of IBS is around 11% according to
the Rome Criteria III [1, 2] and approximately
5% according to the Rome Criteria IV [3]. In
Spain, the prevalence of IBS-based on the
former (Rome Criteria III) is 8.3% [4]. In
addition, the health-related quality of life
(HR-QoL) of IBS patients is relatively low,
comparable to that of patients with diabetes
and heart failure/defect who have a high rate of
mortality [5].
Although the pathophysiology of IBS is not
yet fully understood, various events may be
responsible for the motility and hypersensitivity
disorders associated with the IBS, such as
micro-inflammatory phenomena, changes in
intestinal permeability and in the gut-brain
axis, and alterations to the gut microbiota [6].
IBS is classified into three main subtypes
according to the predominant alteration in
bowel habits: constipation-predominant IBS
(IBS-C), diarrhea-predominant IBS (IBS-D) and
IBS alternating between constipation and
diarrhea (IBS-M) [1]. Patients who meet the
diagnostic criteria for IBS but whose bowel
habits cannot be accurately categorized into
one of these three groups should be categorized
as having unclassified IBS (IBS-U).
In clinical practice, IBS-C represents a
challenge in terms of both diagnosis and
therapeutic management [7], which makes it
necessary to establish specific clinical guidelines
[8]. Currently, the management of this disorder
is based on a combination of lifestyle changes
and the administration of certain non-specific
symptomatic treatments. Linaclotide is a
selective agonist of guanylate cyclase C
(GC-C). The GC-C receptor is expressed on the
luminal surface of intestinal epithelial cells, and
its activation leads to a significant increase in
the intra- and extracellular concentrations of
cyclic guanosine monophosphate (cGMP). This
cGMP is involved in a wide range of
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physiological processes, including the
regulation of intestinal fluid homeostasis
[9, 10] and the modulation of afferent gut
nerve activity, which may be related to its
analgesic effects [11–13]. The efficacy and
safety of linaclotide in patients with IBS-C
have been demonstrated in two randomized,
double-blind, placebo-controlled phase III
multicenter clinical trials [14, 15]. An analysis
of both these trials was published in 2013 [16],
presenting the pre-specified analysis of primary
efficacy end points required by the European
Medicines Agency (EMA). According to the
results of these studies, linaclotide treatment
significantly improved abdominal pain/
discomfort and the overall relief of IBS-C
symptoms compared with a placebo over 12
and 26 weeks (53.6% linaclotide vs. 36.0%
placebo at week 26, [16]). Regarding efficacy,
the odds ratio of a response to linaclotide
relative to the placebo was 1.95 (95%
confidence interval, CI 1.3–2.9: p\0.0001 [16]).
On the basis of a meta-analysis, linaclotide
was shown to improve bowel function and to
reduce abdominal pain and overall IBS-C
severity relative to a placebo [17]. Regarding
safety, the most common treatment-emergent
adverse event (AE) was diarrhea, which was
experienced by approximately 20% of patients
who received linaclotide. In 90% of these
patients diarrhea was considered to be mild or
moderate, and it was only considered to be
severe in 2% of patients, in all of whom it was
resolved within a few days of drug withdrawal
[18]. Thus, the data from clinical trials and the
low bioavailability of the compound make
linaclotide a drug with a favorable safety profile.
Based on the above, in November 2012
linaclotide received European marketing
authorization for the symptomatic treatment
of moderate to severe IBS-C in adults. Indeed, it
is currently the only drug specifically indicated
for the treatment of IBS-C [19]. Linaclotide has
also been approved in the USA by the Food and
Drug Administration (FDA) for the treatment
of IBS-C and functional constipation at a dose
of 290 and 145 lg, respectively [20]. Although
therapeutic management with linaclotide is
relatively simple, some doubts may arise as it is
a first-in-class medication for the treatment of
IBS-C with a novel mechanism of action.
Hence, the purpose of this review is to
evaluate the evidence currently available, as
well as the experiences of a group of clinical
experts with linaclotide, to facilitate and
optimize its use in clinical practice,
establishing common guidelines for patient
monitoring.
METHODS
This article is based on previous studies and
does not involve any new studies carried out
on human or animal subjects by any of the
authors. In May 2016, a group of experts in
gastroenterology was convened to review the
efficacy and safety of linaclotide and to
develop an updated expert consensus report
for the treatment of patients with IBS-C. At
this meeting, the Coordinating Committee for
this project was defined (made up of the first
and second authors of this manuscript), and
all the authors deliberated on the main
questions that need to be addressed
regarding the management of IBS-C patients
treated with linaclotide in daily clinical
practice.
Similarly, a literature search was carried out
in May 2016 for English, French and Spanish
language articles indexed in PubMed or
EMBASE and for abstracts at DDW or UEGW.
The search terms used were ‘‘irritable bowel
syndrome’’ OR ‘‘constipation-predominant
irritable bowel syndrome’’ AND ‘‘linaclotide’’.
Additionally, relevant national and
international guidelines were also scrutinized.
All papers fulfilling these criteria were studied
before drafting the consensus. An initial version
of the guidelines was produced by the
Coordinating Committee, and it was reviewed
by the expert panel who recommended
modifications. The Coordinating Committee
evaluated the panel’s comments and drafted a
document that included the necessary
modifications. Subsequent revisions were
performed based on feedback from all the
authors until a consensus was reached on the
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final validated text at a meeting held in October
2016.
RESULTS
The strategy to manage IBS-C patients with
linaclotide and an overview of the
recommendations proposed by the expert
panel are summarized in Tables 1 and 2,
respectively.
Linaclotide Prescription
According to the summary of the product’s
characteristics (SmPC), linaclotide is indicated
for the treatment of adults with moderate to
severe symptomatic IBS-C (defined as symptoms
that significantly impair the patient’s QoL or
daily activities [18–20]). Linaclotide can be
prescribed as a first-line therapy but in some
countries, such as Spain, the National Health
System reimburses the drug only in those
Table 1 Management strategy for linaclotide treatment in adult patients with constipation-predominant irritable bowel
syndrome
Follow-up monitoring First follow-up visit Subsequent follow-up visits
Clinical
assessment
4 weeks 12 weeks Individualized monitoring
according to the patient’s
needs
Efficacy
Bowel habits Quick effect: must be adequate and
satisfactory in terms of the
patient’s stool frequency and
consistency
There is no tachyphylaxis
(reduced responsiveness)
There is no tachyphylaxis
(reduced responsiveness)
Pain/bloating Gradual effect: possible
improvement
Fully improved There is no tachyphylaxis
(reduced responsiveness)
Tolerability Diarrhea may occur, which is
usually mild and transient
Monitor Monitor
Adherence Monitor correct compliance Monitor correct compliance Monitor correct compliance
Drug
withdrawal
In cases of severe or prolonged
diarrhea (i.e., more than
1–2 weeks) consider
discontinuing the treatment until
the episode is resolved
If the clinical objectives have not
been reached by week 12, drug
withdrawal can be considered.
However, before stopping the
treatment, the doctor should
evaluate treatment adherence,
changes in lifestyle and dietary
habits, and concomitant
treatments that might potentially
interact with linaclotide (opioids,
neuroleptics, or tricyclic
antidepressants)
The need to maintain
continuous treatment with
linaclotide must be
regularly assessed by the
doctor
Treatment
combinations
If there is a partial response to linaclotide, the association of laxatives is a reasonable option that should be
evaluated, as well as the association of spasmolytic and/or antidepressant drugs in the case of a partial
pain response
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patients who do not adequately respond to
other available treatments. The recommended
daily dose of linaclotide is 290 lg (one capsule).
Linaclotide is only contraindicated in
patients with known or suspected mechanical
gastrointestinal obstruction or in those who
display hypersensitivity to linaclotide or to any
of its excipients [18, 21]. When prescribing
linaclotide it is essential that doctors provide
the patient with the following information,
advice and warnings:
1. To follow the lifestyle and dietary advice
generally recommended in IBS-C [22].
2. Linaclotide should be taken at least 30 min
before a meal as taking linaclotide
immediately after a high-fat breakfast
results in more frequent and looser stools
as well as more gastrointestinal AEs than
when taken in the fasted state [18].
3. Linaclotide should be taken continuously
since sporadic administration seems to be
ineffective.
4. Since diarrhea occurs in approximately 20%
of patients [14–18], it is advisable to warn
the patient of this possibility and make the
adequate recommendations. In most cases,
diarrhea appears during the first week of
treatment, and in one-third of cases it
disappears within 7 days without
discontinuing the treatment.
5. When starting the treatment with
linaclotide, all drugs and herbal products
with a laxative effect should be
discontinued to decrease the likelihood of
diarrhea.
6. Although no drug interactions have been
described, it seems reasonable to be
cautious when prescribing drugs absorbed
in the intestinal tract with a narrow
therapeutic index (i.e., anticoagulants,
thyroid hormones, contraceptives, etc.) as
their efficacy might be reduced.
Linaclotide Efficacy
As mentioned above, the efficacy of linaclotide
has been demonstrated in two randomized,
double-blind and placebo-controlled phase III
multicenter clinical trials [14, 15]. However, the
evidence suggests that clinical improvement in
pain and bloating symptoms may not appear
until after 4 weeks of treatment. Thus,
physicians should periodically assess the need
for continued treatment, and if patients have
not experienced any improvement in their
symptoms after 4 weeks of treatment, the
benefit and risks of continuing treatment
should be reconsidered. Hence, specific
recommendations have been established to
facilitate decision-making.
What Clinical Improvements Can Be Expected
After Initiating Linaclotide Therapy?
The phase III linaclotide clinical trials showed a
significant improvement in the frequency of
spontaneous bowel movements from the first
week of treatment onwards [14–16]. However,
pain and abdominal distension improved
gradually, with partial relief after 4 weeks,
while maximal effects were not observed until
week 10 [14–16].
When Are Follow-Up Visits Recommended
After Initiating Linaclotide Treatment?
Based on the above, it seems reasonable to
recommend that the first follow-up visit (or
telephone interview) should take place 4 weeks
after initiating the treatment and the second
one after 3 months. Thereafter, physicians
should periodically assess the need for
continued treatment according to the
individual patient.
What Clinical Variables Should Be Taken
into Consideration at Each Control Visit?
1. Tolerability and adherence.
2. Bowel habits, with the expectation that a
satisfactory and adequate stool frequency
should be achieved by the first follow-up
visit (week 4).
3. Pain and abdominal distension would be
expected to show some improvement by
week 4; however, the peak analgesic effect
would be expected from week 10 onwards,
and therefore it would be better assessed at
week 12.
If these clinical objectives have not been
reached by week 12, drug withdrawal should
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be considered. However, treatment adherence,
lifestyle and dietary habit changes, and
concomitant treatments should be evaluated
before stopping the treatment as these factors
might possibly affect linaclotide efficacy (e.g.,
opioids, neuroleptics or tricyclic
antidepressants).
To assess its effectiveness in relieving
constipation, bloating and pain in patients
with IBS-C, the continuous use of linaclotide
is recommended. To date, it is unclear whether
linaclotide is suitable to treat unusual or
sporadic disease outbreaks. Although the
therapeutic response must be evaluated and
agreed upon with the patient, it seems
reasonable to recommend continuing the
treatment until week 12 to have a chance to
achieve the maximal clinical effect [22].
When Would Administering Linaclotide
as a Combined Therapy be Recommended?
As far as we know, there are no studies that have
evaluated the potential therapeutic benefit of
linaclotide in association with other treatments.
Nevertheless, patients included in both the
phase III trials carried out to date who were
taking stable doses of fiber, bulk laxatives, stool
softeners or probiotics for 30 days prior to the
screening visit were allowed to continue this
treatment during the course of the study [14].
From a pharmacodynamics point of view,
linaclotide has a different mechanism of
action from other drugs used to treat IBS-C;
thus, it seems plausible that combining them
might have a synergistic effect. Therefore,
combining linaclotide with other therapies
would appear to be safe and in some patients
might even be desirable. Hence, if linaclotide
Table 2 Overview of the expert panel’s recommendations
Recommendation
Medical prescription of
linaclotide
Linaclotide is indicated for the symptomatic treatment of moderate to severe
constipation-predominant irritable bowel syndrome (IBS-C)
Medical prescription—
recommendations
To adopt the lifestyle habits and foods recommended for IBS-C
To take the drug 30 min before a meal, preferably with breakfast
It is recommended to take linaclotide continuously, not sporadically
It is advisable to warn the patient about the incidence of diarrhea and make the adequate
recommendations
The patient should be informed about the rapid effect on the intestinal symptoms and
gradual effect on the abdominal ones
To distance administration from the intake of oral drugs with a narrow therapeutic margin
Linaclotide in combination
with other drugs
Patients with a partial response in bowel habits: evaluate the association of laxatives
Patients with a partial response in abdominal pain: evaluate the association of spasmolytics
and/or antidepressants
Long-term treatment Linaclotide can be maintained for a long period of time, since there is no tachyphylaxis or
evidence of potential risks
Treatment withdrawal In responders, linaclotide treatment must be maintained for 6–12 months. The possibility
of stopping the treatment may be considered after taking into consideration the time
needed to achieve a therapeutic effect
Treatment reintroduction If after the withdrawal of linaclotide, its reintroduction can be considered following the
same therapeutic regimen as that used initially
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does not provide full relief of a patients’
symptoms, physicians might consider
combining it with other drugs or therapies,
such as laxatives and/or antispasmodics.
Should We Increase the Dose of Linaclotide
in Refractory Patients?
The scientific evidence available indicates that
linaclotide efficacy does not significantly
increase when doubling the recommended dose
[23]. However, there are no data currently
available as to whether such an increase could
benefit refractory patients or partial responders.
Moreover, it appears that linaclotide is safe at
doses as high as 600 lg in IBS-C patients over a
12-week treatment period and up to 2897 lg as a
single dose in healthy volunteers [23, 24].
Furthermore, other experimental studies have
shown that gastrointestinal transit accelerates as
the dose administered increases [24, 25]. In
summary, the evidence currently available
indicates that the strategy of increasing
linaclotide dose in patients who are partial or
non-responders cannot be routinely
recommended. Nevertheless, the good safety
profile of linaclotide means that increasing the
dose might be considered on an individual basis.
Tolerability
Diarrhea is the most common AE experienced
by those receiving linaclotide treatment,
consistent with its pharmacological action.
Diarrhea was reported in 20% of patients in
clinical trials, with approximately 5% of
patients withdrawing from the two studies
because of side effects [14, 15]. Approximately
half of the diarrhea episodes started within the
first week of treatment, although nearly one
third of diarrhea cases were resolved within
7 days, even if treatment continued [18].
Diarrhea is the result of the pharmacological
action of the active substance, and in clinical
practice, its consideration as an AE differs
among patients. Many patients perceive
diarrhea not as an adverse effect but rather as
a sign of drug activity, the patient’s reportedly
being satisfied with the drug despite this AE. In
clinical trials, IBS-C patients on linaclotide who
reported diarrhea had similar treatment
satisfaction relative to those who did not
report diarrhea, and[85% were moderately to
quite satisfied during 2 years of treatment [26].
If Diarrhea Occurs, How Should It Be Dealt
with?
Since diarrhea depends on the pharmacological
effect of the drug itself, it is important to inform
the patient of this possible side effect at the
time of prescription and to provide them with
guidelines as to how to act.
Options to help combat side effects such as
diarrhea:
1. Linaclotide should be taken at least 30 min
before a meal.
2. Linaclotide should not be taken with food.
3. Linaclotide should ideally not be
co-administered with laxatives at the
beginning of the treatment.
However, even if mild or moderate diarrhea
continues, doctors might recommend that
patients continue the treatment at the
recommended dose until its full impact on
their symptoms can be assessed, particularly
since in 30% of cases this diarrhea disappears
despite maintaining treatment.
From a practical point of view, diarrhea can be
considered as:
Mild: when it is perceived by the patient as a
drug effect that does not interfere with their
daily activities.
Moderate: Diarrhea that interferes with the
patient’s daily activities but from the patient’s
point of view the inconvenience is less
important than that produced by their IBS.
Severe: Diarrhea interferes with the patient’s
QoL, and it is considered to be unacceptable.
Because the incidence of diarrhea in clinical
studies is dose dependent, in those patients
considering diarrhea as an AE the best option is
to reduce the dose. Since there are currently no
preparations with lower doses commercially
available in Europe, an option is to administer
one capsule every 48 h and resume the daily
dosage when the diarrhea has been resolved.
Although it is not known whether the
pharmacodynamic properties of the
preparation are the same under these
conditions, there is some recent evidence
Adv Ther (2017) 34:587–598 593
supporting dose reduction as an option to
decrease the incidence of diarrhea without loss
of efficacy. A clinical trial comparing the
administration of two different doses (145 and
290 lg) of linaclotide in patients with chronic
constipation and bloating concluded that lower
doses were associated with the occurrence of
diarrhea in 5.9% of cases compared to 16.9% in
the patients that received the higher dose (2.3%
in the placebo group). Surprisingly, the clinical
results were similar in both groups of patients
[27].
Have Any Drug Interactions Been Described
for Linaclotide?
Linaclotide is a drug that acts locally in the
gastrointestinal tract, where dityrosine, itsmajor
active metabolite, is virtually not absorbed. Both
linaclotide and dityrosine are reduced and
proteolyzed in the digestive tract, being
processed into smaller peptides and amino
acids that may be found naturally in the body.
Linaclotide and its active metabolite are rarely
detected in plasma after oral administration of
therapeutic doses, which makes it highly
improbable that it interacts with other systemic
drugs. In vitro studies have shown that neither
linaclotide nor its activemetabolite are clinically
significant inhibitors of the most important
carriers of the uptake and efflux of drugs [21].
So it is unlikely that there is any interferencewith
the active absorption of other drugs.
However, although the data suggest no
interaction between linaclotide and other
drugs, it is important to note that the
absorption of orally administered drugs may
be affected in patients who suffer prolonged
diarrhea, requiring special consideration of
drugs that are absorbed in the intestinal tract
and that have a narrow therapeutic index
[18–21]. Based on in vitro studies, linaclotide
does not interact with the cytochrome P450
enzyme system [18–21].
Is It Possible to Combine Linaclotide
with Proton-Pump Inhibitors or Non-Steroidal
Anti-Inflammatory Drugs?
Based on the SmPC, the concomitant
administration of linaclotide with
proton-pump inhibitors (PPIs) or non-steroidal
anti-inflammatory drugs (NSAIDs) could
increase the incidence of diarrhea [21]. Both
PPIs and NSAIDs are widely used drugs, and
they are associated with diarrhea as an AE. Thus,
linaclotide may increase the incidence of
diarrhea, although there is no clear evidence
of this.
From a clinical perspective, discontinuation
of PPIs and NSAIDs is not recommended when
prescribing linaclotide, unless these treatments
are inappropriate. Should a patient taking such
drugs suffer diarrhea, the following issues
should be assessed:
1. The indication for which the PPIs and
NSAIDs are prescribed and possible
alternatives.
2. The potential clinical benefit obtained with
the treatment of linaclotide.
Long-Term Management
How Long Do I Have to Treat a Patient
with Linaclotide?
There is evidence suggesting that 2–5% of IBS
patients were diagnosed with an alternative
organic gastro-intestinal disorder after a
6-month to 6-year follow-up [28], indicating
that IBS is a stable diagnosis. IBS is a chronic
disorder that is characterized by the presence of
recurrent gastrointestinal symptoms whose
duration varies among patients [1, 29]. A
significant proportion of IBS patients have
symptomatic episodes for years that may need
long-term treatment [29, 30]. Moreover, phase
III linaclotide clinical trials demonstrated
efficacy through week 26 (6 months) [14, 15].
A preliminary report of a long-term study
evaluated tolerability and patient satisfaction
in patients with IBS treated with linaclotide
over a period of 18 months [26]. The results of
this study suggested that linaclotide was well
tolerated and that diarrhea did not negatively
affect patient satisfaction [26].
Both scientific evidence and clinical
experience show that linaclotide can be
maintained for a long period of time, since
there is no tachyphylaxis or evidence of
potential risks from pharmacovigilance studies
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(linaclotide has been on the market from 2012
in the USA and 2013 in Europe).
Can Linaclotide Be Withdrawn
in a Responder?
As previously mentioned, IBS alternates
symptomatic and asymptomatic periods [28],
so the need to maintain continuous treatment
with linaclotide must be regularly assessed
[18–21]. In this clinical scenario there are two
important considerations:
1. The possibility of a rebound effect after
treatment withdrawal. However, the
efficacy of linaclotide has been evaluated
over a period of 26 weeks in 803 patients
who were randomized (1:1) to receive either
linaclotide or a placebo [15]. At week 12, the
patients in the linaclotide group (406) were
again randomized (1:1) to continue with
linaclotide or to receive the placebo. Drug
withdrawal meant a rapid drop in the
number of complete spontaneous stools
per week to the levels observed in the
placebo group. Simultaneously, the
patients experienced a progressive increase
in abdominal pain, again similar to that
observed in the placebo group [15].
Therefore, a rebound effect should not be
expected after linaclotide removal but
rather a loss of its pharmacological effect
that places the patient at a similar
symptomatic level as those who receive a
placebo.
2. The possibility of using the drug whenever
the symptoms arise. There is no scientific
evidence supporting this strategy, and the
assumptions must be made based on
clinical trial results. Linaclotide has a rapid
effect on bowel habits and constipation
symptoms (less than 1 week), whereas its
antinociceptive effect is slower and
progressive (at least 1 month to reach the
maximum effect). Therefore, in patients
referring to constipation as the most
bothersome symptom of IBS-C, the option
of stopping treatment and restarting it
when symptoms appear can be discussed,
since the therapeutic response is fast.
However, this strategy is not
recommended in those patients who refer
to pain or bloating as the most bothersome
symptom of IBS-C, since the recurrence of
these symptoms requires us to wait for at
least 4 weeks to obtain a therapeutic effect.
Overall, prolonged linaclotide treatment in
responding patients should be maintained for
between 6 and 12 months. Furthermore,
stopping treatment can be considered with the
patient’s consent, taking into consideration the
time needed to achieve a therapeutic effect.
What Would the Appropriate Treatment Dose
of Linaclotide Be in Patients Who Had
Previously Withdrawn Their Treatment?
After linaclotide withdrawal for any reason, it
shouldbe reinstated,whenconsiderednecessary,
at the same dose as that used initially. Regarding
the effectiveness of rechallenge, once linaclotide
has been suspended, there is evidence suggesting
that a positive clinical response is quickly
restored [14]. In addition, patient satisfaction
appears to improve and is maintained for a
prolonged period [31].
Special Populations
Pregnancy
It is advisable to avoid the use of linaclotide
during pregnancy as there are insufficient data
regarding its safety in pregnant women. Animal
studies do not indicate direct or indirect
harmful effects with respect to reproductive
toxicity [18–21].
Pediatric Population
Linaclotide is contraindicated in children under
6 years of age [18–21]. To date there are no
studies evaluating the efficacy and safety of
linaclotide in pediatric patients. To clarify these
facts, a clinical trial in patients with IBS-C
between 7 and 17 years is being carried out [32].
Elderly Patients
Patients older than 65 years represented 5.3% of
the patients included in the phase III clinical
trials [16]. These patients reported diarrhea
more frequently than the overall IBS-C
population in the clinical trial. Although no
dose adjustment is required, treatment of
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elderly patients should be carefully monitored
and periodically re-assessed.
Patients with Hepatic or Renal Impairment
Linaclotide has not been studied in patients
with renal or hepatic impairment. However, as
linaclotide is rarely detected in plasma and its
by-products are not metabolized by liver
cytochrome P450 enzymes, renal or hepatic
impairment would not be expected to affect the
metabolism or clearance of the drug or its
metabolites.
Inflammatory Bowel Disease Patients
Linaclotide has not been studied in patients
with chronic inflammatory conditions of the
intestinal tract, such as Crohn’s disease and
ulcerative colitis.
CONCLUSIONS
Irritable bowel syndrome is a highly prevalent
chronic functional gastrointestinal disorder
with a complex underlying pathophysiology.
It is characterized by abdominal pain and/or
discomfort, altered bowel function and a
recurrence of symptoms over an extended
period of time. Altered bowel function, a
hallmark of IBS, may present as constipation
(irritable bowel syndrome with constipation),
diarrhea or alternating periods of constipation
and diarrhea (mixed irritable bowel
syndrome).
Despite their widespread use, traditional
treatments for IBS-C are of limited
effectiveness in improving IBS symptoms, such
as bulking agents, stool softeners, laxatives and
antispasmodics. Linaclotide is a selective
agonist of GC-C, which is selectively expressed
in the brush border membranes of the intestinal
mucosa from the duodenum to the rectum. The
results of clinical trials have demonstrated that
linaclotide can improve a wide spectrum of IBS
symptoms in patients with IBS-C, including
abdominal pain, bloating and constipation.
The panel agrees to recommend taking the
drug 30 min before a meal, preferably
breakfast. Additionally, it is advisable to
warn the patient about the incidence of
diarrhea and make adequate
recommendations to avoid this side effect.
This consensus highlights key elements that
will help clinicians standardize linaclotide use
in clinical practice, establishing common
guidelines to monitor patients.
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